Skip to main content
OpenTrials

Clinical trial condition

Urethral Neoplasms

Explore clinical trials studying Urethral Neoplasms. Study availability and eligibility vary by location and protocol.

82 public trials 7 recruiting studies
Refine in advanced search Browse all conditions

Urethral Neoplasms trial results

Completed

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

NCT02178241

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +20 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles County-USC Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Keck Medical Center of USC Pasadena Pasadena, California, United States
View all 18 locations
View Trial Details
Completed

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

NCT01282463

Conditions
Adenocarcinoma, Carcinoma, Carcinoma of Renal Pelvis, +21 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Los Angeles, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Sacramento, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. San Francisco, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Aurora, Colorado, United States
View all 32 locations
View Trial Details
Completed

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

NCT01191892

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +16 more
Locations
  • Beatson West of Scotland Cancer Centre Glasgow, Scotland, United Kingdom
  • Wales Cancer Trials Unit Cardiff, Wales, United Kingdom
  • Ayr Hospital Ayr, United Kingdom
  • Royal Bournemouth General Hospital Bournemouth, United Kingdom
View all 21 locations
View Trial Details
Completed

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

NCT01089088

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
Locations
  • Bristol Haematology and Oncology Centre Bristol, Avon, United Kingdom
  • Castle Hill Hospital Cottingham, East Yorkshire, United Kingdom
  • Royal Bournemouth Hospital Bournemouth, England, United Kingdom
  • Churchill Hospital Oxford, Oxfordshire, United Kingdom
View all 16 locations
View Trial Details

Related conditions